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The childhood-onset genetic motor neuron disease spinal muscular atrophy (SMA) is 
characterized by progressive weakness, muscle wasting and, for the most severely affected 
patients, premature death. SMA is caused by loss of SMN1, leading to low levels of full-length 
survival motor neuron (SMN) protein. Excitingly, the disease-modifying therapy nusinersen 
(marketed by Biogen as SpinrazaTM), has recently been approved for SMA.  Nusinersen is an 
antisense oligonucleotide (ASO) delivered intrathecally to specifically correct the genetic 
defect that underlies SMA and restore SMN protein levels. Many SMA patients benefit greatly 
from nusinersen and other forms of SMN-targeted therapies that are currently in various 
stages of clinical development. However, initial clinical studies also illustrate several limitations 
of SMN-targeted therapies, including the requirement for a very early treatment start and 
uncertainty around the long-term efficacy of targeting treatment exclusively to the central 
nervous system. Here, I will discuss possible further avenues for SMA therapy development 
beyond current SMN-targeted therapies, focusing on how basic and clinical lines of research 





Spinal muscular atrophy (SMA) is a motor neuron disease leading to progressive weakness, 
muscle wasting and, for the most severely affected patients, premature death [1]. SMA is 
caused by homozygous deletion of, or loss-of-function mutations in, the survival motor neuron 
1 gene (SMN1). A second SMN gene (SMN2) that is alternatively spliced partially 
compensates for this loss, but only produces low levels of full-length SMN protein [2]. Since 
this discovery, combined efforts from researchers, clinicians and the SMA patient community 
have led to the development and recent approval of a disease-modifying therapy, nusinersen 
(marketed by Biogen as SpinrazaTM). Nusinersen is an antisense oligonucleotide (ASO) 
delivered directly into the central nervous system (CNS) by intrathecal injection to specifically 
correct the genetic defect that underlies SMA by targeting SMN2 splicing. Similarly, other 
SMN-targeted therapies that aim to increase SMN levels either by correcting SMN2 splicing 
or replacing SMN1 are currently in various stages of development.  
Early findings from clinical trials and subsequent follow-up studies indicate that many 
SMA patients benefit greatly from nusinersen and other forms of SMN-targeted therapies [3-
5]. However, the same studies also illustrate several limitations of SMN-targeted therapies. 
For example, not all patients benefit equally from SMN-targeted therapies, and early 
commencement of treatment provides most benefit, but is not always feasible. These findings 
are generally in line with previous preclinical studies, which showed that there is a limited 
therapeutic window available to start SMN-targeted therapy in animal models of SMA [6]. 
Importantly, preclinical studies also indicated that CNS-specific restauration of SMN was not 
sufficient to provide complete rescue of the SMA phenotype in animal models [7], which 
suggests that current nusinersen therapy for SMA may lead to the development of further, 
non-CNS symptoms in SMA patients as they get older. Therefore, the approval of nusinersen 
represents an important moment for the SMA research field to determine and discuss key 
questions that need to be addressed in the coming years in order to provide optimal therapies 
and support. Here, I will focus on possible avenues for SMA therapy development beyond 
current SMN-targeted therapies.   
 
2. Dissecting the cellular consequences of SMN depletion 
 
Because the genetic cause of SMA has long been known, significant research efforts have 
focused on understanding the cellular changes that occur when levels of SMN are reduced. 
Initial studies linked SMN to the biogenesis of small nuclear ribonucleoproteins (snRNPs), the 
protein-RNA complexes that are required for spliceosome formation [8]. This was later 
extended to general RNP biogenesis, as SMN was shown to be involved in the formation of a 
number of similar RNP complexes [9]. Because of this role, the function of SMN in RNA 
splicing has been extensively studied. Although SMN plays an important role in splicing, 
splicing defects in SMA appear to occur late in pathogenesis and might not be directly linked 
to cell type specific pathology, although this remains to be definitively determined [10,11].   
Since, SMN has been shown to be involved in a wide range of cellular pathways that 
are required for neuronal and synaptic homeostasis. These pathways include endocytosis, 
cytoskeletal dynamics, mitochondrial function and ubiquitin homeostasis [12-18]. Current 
issues in SMA research that will need to be addressed is the question of whether and how 
these pathways are related, to what extent SMN plays a central role in each of these pathways, 
and whether other master regulators or modifiers exist that interact with or control SMN 
function (Figure 1). For this to be successful, it will be important to first better understand the 
biological role of SMN independent of SMA, as it will allow identification and dissection of key 
cellular pathways in a non-disease context [19]. In trying to identify molecular mechanisms 
that link previously identified SMN-dependent molecular mechanisms, an interesting 
hypothesis is that of altered protein homeostasis as a central regulator of disease pathways 
in SMA. Correct protein turnover by local translation and degradation is required for neurons 
and synapses to function properly, and interestingly, both these pathways have been shown 
to be affected in SMA and to depend on SMN [15,20,21]. However, the exact role of SMN in 
both pathways remains to be determined in more detail and is likely to involve a complex 
interplay between multiple cellular pathways and mechanisms.   
 
3. Using insights from basic research to inform further clinical development 
 
Considering the emerging limitations of SMN-targeted therapies and the broad range of 
cellular pathways that have been linked to SMN function and SMA pathology, SMN-targeted 
therapies will likely need to be combined with other therapeutics that target other proteins and 
pathways to provide all-round treatment and stop disease progression. Indeed, a significant 
number of such proteins and pathways have already been identified in SMA (see section 2 
and e.g. [22]). As the number of SMA patients is relatively small, careful consideration will be 
required to determine which targets should eventually be taken forward into clinical studies. 
This will require a pragmatic approach as certain targets may be very promising in animal 
models, but technically and pharmaceutically challenging to implement in human patients. 
This further emphasizes the need for studies that aim to identify central regulators of SMA 
pathology and the precise hierarchy between pathways (Figure 1). Moreover, it will be 
necessary to develop improved animal models that better reflect the post-nusinersen clinical 
landscape, i.e. models that are based on genetic depletion of SMN followed by postnatal 
pharmacological restoration of SMN expression (for example [23]). Standardizing these 
models across labs and across the main mouse models for SMA is likely to be an important 
point of focus for the SMA field in coming years, including the optimization of more sensitive 
phenotypic readouts for mouse models that allow to reliably assess neuromuscular function 
at a range of developmental stages. These preclinical studies will have to be complemented 
by more detailed clinical phenotyping of SMA patients, including comparative studies of the 
natural history of SMA patients before and after nusinersen approval. Also, current outcome 
measures for clinical trials may need further refinement in order to successfully investigate 
combinatorial therapies. This may include further optimization of existing tests but may also 
include the development of further biomarkers based on lab- and imaging-readouts to expand 
current possibilities for more refined measurements of disease state and progression. As 
before, extensive crosstalk between preclinical and clinical lines of research will remain vital 




Research in recent years has led to a substantially increased understanding of SMA. The 
diversity of novel SMN-associated molecular mechanisms, and cellular pathways affected in 
SMA illustrates the complexity of the processes that underlie motor neuron degeneration. This 
complexity forms a challenge, but also provides more starting points for understanding SMA 
pathology and identify further therapeutic targets. Combined with evolving knowledge on the 
long-term effect of SMN-targeted therapies, the SMA field is likely to develop considerably in 
years to come.  
 
5. Expert opinion 
 
The development and approval of nusinersen represents a crucial and historic moment in SMA 
research, comparable to the discovery of SMN1 deletion as the cause of SMA and the 
discovery of alternative splicing of SMN2. SMA research leading up to the approval of 
nusinersen has been relatively straightforward, as it focused on how to specifically target a 
single genetic defect and increase patient survival. Moving forward, SMA research will enter 
a more complex phase, in which novel therapies will need to be compared to existing ones. 
Moreover, future research will need to consider the overall health and quality of life of patients, 
and as such look for more subtle changes, all in a relatively small and limited group of 
vulnerable patients.  
In the past, developments in understanding the genetic basis of SMA have guided 
SMA research. Similarly, the consequences of the approval of nusinersen will have to guide 
current and future research, thereby refocusing and informing priorities. Clinically, the 
observation, characterization and follow-up of patients that have been treated with nusinersen 
and possible future SMN-targeted therapies will be of vital importance. These studies will need 
to lead to the development of more detailed outcome measures for therapeutic studies and 
better insights into patients’ expectations and requirements that are likely to arise from 
changing disabilities. Scientifically, the SMA field will need to update existing, and develop 
novel, model systems that better reflect the new patient situation and improve the 
understanding of how cellular pathways that are affected in SMA are related. Combined, this 
is likely to lead to a shift of focus in therapy development from survival to symptoms and quality 
of life, and from SMN replacement to SMN-combination therapies. This will broaden current 
SMA drug development avenues and eventually lead to an extended arsenal of therapeutic 
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Figure 1. Possible involvement of SMN protein in cellular pathways and downstream 
consequences.  
Many cellular pathways have been linked to SMN function and SMA pathogenesis. What is 
currently unknown, is how and if these pathways are functionally related. For this, several 
possibilities can be proposed, each requiring further investigation. First, SMN could separately 
regulate or be involved in multiple cellular pathways (1A). Second, SMN might regulate one 
or several master regulators or central pathways, such as protein translation and degradation, 
that in turn affect the function of multiple, downstream pathways (1B). Finally, SMN depletion 
in SMA might start a cascade of cellular defects that could be further regulated by central 
pathways or other proteins and form a combined cause of pathology (1C). Many modifiers of 
SMA pathogenesis have already been identified (see e.g. [22]) and therefore RhoA/ROCK, 
PLS3/COROC1 and PGK1 serve as examples of distinct pathways that have been shown to 
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